* * * Certain information in this agreement
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.


 


FEASIBILITY AND OPTION AGREEMENT


 


THIS FEASIBILITY
AND OPTION AGREEMENT (the “Agreement”) is made and entered into as of June 20, 2007 by and
between LIPOCINE, INC., a Delaware corporation having its principal place of business at 675 Arapeen Drive, Suite 202, Salt
Lake City, UT 84108 (“Lipocine”), and KRELE PHARMACEUTICALS, INC., a Delaware corporation
having its principal place of business at 1349 Lexington Avenue, Suite 2C, New York, NY 10128 (“Krele”).
Lipocine and Krele may be referred to herein individually as a “Party”, or collectively as the
“Parties”.


 


		1.	OVERVIEW



 


1.1       This
Agreement provides for: (a) a feasibility and phase I study to be conducted by Lipocine with Krele funding, to study the feasibility
of oral delivery of cyclobenzoprine (the “Product”) using Lipocine’s delivery technology (the “Feasibility
Study”), and (b) the grant to Krele of an exclusive option to negotiate and enter into an exclusive license under
the applicable Lipocine technology and intellectual property to develop and commercialize the Product upon payment of $[* *
* ] towards the cost of the Feasibility Study. The Lipocine technology that will be used in the Feasibility Study and available
under such option includes Lipocine's Lip'ralTM technology for improving absorption of poorly water-soluble compounds.


 


		2.	FEASIBILITY PROGRAM



 


2.1       Feasibility
Program. Lipocine shall conduct a Feasibility Study to assess the feasibility of improved oral delivery of the Product
for Krele in accordance with the Feasibility Study protocol attached to this Agreement as Exhibit I and incorporated herein
(the “Protocol”). Lipocine shall conduct the Feasibility Study exclusively for Krele in a diligent, professional
and workmanlike manner. The cost and timelines for conducting the Feasibility Study are as specified in the Protocol. Upon the
completion of the Feasibility Study, Lipocine shall deliver the final report as contemplated by the Protocol (the “Final
Report”). Krele will promptly review the results of the Feasibility Study as set forth in the Final Report. If Krele
determines that it desires to proceed with its option to license, Krele will so notify Lipocine in writing no later than thirty
(30) days after receipt of the Final Report).


 


		3.	OPTION FOR EXCLUSIVE LICENSE



 


   3.1          Option
to License.


 


(a)       Lipocine
hereby grants to Krele the exclusive option (the “Option”) to obtain an exclusive, worldwide license
under the Lipocine Intellectual Property (as defined below) for the further development and commercialization of the Product, on
the terms and conditions set forth in this Section 3. Krele may elect to exercise the Option by providing Lipocine written notice
of such election no later than thirty (30) days after receipt of the Final Report.


 



    	1



    	 



    

 


(b)       If
Krele exercises the Option, then the Parties will meet promptly thereafter and negotiate in good faith a license agreement that
grants Krele or an affiliate the exclusive, worldwide license and rights under the Lipocine Intellectual Property to further develop,
make, have made, offer for sale, sell, import and use the Product, which license agreement shall be on the terms set forth below
and shall contain such other commercially reasonable terms as are customary in the industry for similar license agreements.


 


(c)       During
the term of the Feasibility Study and the Option Period (as defined in Section 3.1(d) below), Lipocine agrees to make available
to Krele all data, know-how and information related to the Product and Lipocine Intellectual Property that is in Lipocine’s
possession or control and that is reasonably necessary or useful to Krele in order for Krele to exercise its Option and determine
an appropriate regulatory strategy for the Product.


 


(d)       The
Parties understand and agree that if, despite the Parties’ good faith negotiations, the Parties are not able to reach final
agreement on a definitive license agreement on the terms provided herein within sixty (60) days after commencing such negotiations
(or such longer period as agreed to by the Parties) (the “Option Period”), neither Party will be obligated
to proceed further with such negotiations.


 


3.2          Scope
of Exclusive License.


 


(a)       The
license rights covered by the Option will be an exclusive, worldwide license, including rights to sublicense, under the Lipocine
Intellectual Property solely to develop, make, have made, offer for sale, sell, import and use the Product. Under the terms of
such license, Krele, its affiliates, and/or its sublicensees will own exclusively all data, regulatory filings and regulatory approvals
covering the Product. For purposes of this Agreement, “Lipocine Intellectual Property” means the patents
and know-how rights owned or otherwise controlled by Lipocine that claim or cover, or directly relate to, the Lipocine oral delivery
technology that is, or may be, used in the Product.


 


(b)       During
the term of the license agreement, in no event shall Lipocine license, transfer or sell the Lipocine Intellectual Property to a
third party for the development, manufacture, use, sale or commercialization of cyclobenzaprine products.


 


(c)       If
development of the formulation selected by Krele reveals that the formulation is not optimal, in Krele’s judgment, Krele
has the option to have Lipocine redevelop one of the formulations from the Feasibility Study that Krele did not initially select
with reimbursement of reasonably incurred costs to Lipocine.


 



    	2



    	 



    

 


* * * Certain information in this agreement
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.


 


3.3       Payments
for Exclusive License. The Parties understand and agree that the payment provisions provided in this Section 3.3 relate to
all Products based on cyclobenzaprine. For the avoidance of doubt, the milestone payments will be paid only once for the first
Product that is bioequivalent to cyclobenzaprine 5 mg. Krele contemplates developing at least four Products that are bioequivalent
to cyclobenzaprine 5 mg: for muscle spasm, sleep, generalized anxiety and fibromyalgia, and no additional milestones will be paid
for such Products. If Krele develops Products that are bioequivalent to other products (for, example, a product that is bioequivalent
to cyclobenzaprine 10 mg), such Products will be considered additional Products and Krele will pay [* * * ]%) of the milestones
set forth in Section 3.3(d) below for the second and third additional Products only.


 


(a)       License
Fee. In the event the Parties enter into a license agreement for the Lipocine Intellectual Property as provided herein, Krele
will pay Lipocine a license fee of $300,000 within ten (10) days of the effective date of the license agreement.


 


(b)       Product
Development Reimbursement. If Krele decides to engage Lipocine to assist Krele in the further development of the Product, then
and only then, as provided in the license agreement, Krele will reimburse Lipocine for all of Lipocine's research and development
expenses relating to Lipocine's activities in support of development of the Product as directed by Krele. Such research and development
expenses will be more fully defined in a product development plan approved by Krele prior to Lipocine incurring any such costs.


 


(c)       Sublicense
Payments. Krele will pay to Lipocine payments equal to [* * * ]%) of any pre-commercialization or commercialization
consideration (e.g., upfront license fees, milestone payments, license maintenance fees, royalties, etc.) received by Krele from
a sublicensee, including any such pre-commercialization consideration received as a result of NDA (or equivalent) approval or Product
launch.


 


(d)       Milestones.
Krele will pay Lipocine milestone payments for the following events:


 


	 	1)	[* * * ]
	 	 	 
	 	2)	[* * * ]


 


In addition, as provided
in Section 3.3 above, if Krele develops Products that are bioequivalent to products other than cyclobenzaprine 5 mg, such Products
will be considered additional Products and Krele will pay [* * * ]%) of the milestones set forth above for the second and
third additional Products only.


 


(e)       Royalties.
Krele will pay to Lipocine royalties based on sales of Product by Krele and its affiliates, which royalties equate to [* * *
]% of net sales.


 



    	3



    	 



    

 


3.4       Understandings.
The Parties understand and agree that consummation of the above proposed licensing transaction is contingent upon execution and
delivery of the contemplated license agreement in a form satisfactory to both of the Parties, which will include the terms and
conditions of Section 3.3 above as well as additional terms and conditions customary for a transaction of this nature, including
without limitation, technology transfer provisions, customary representations and warranties, indemnification provisions and intellectual
property prosecution and enforcement provisions, and neither Party shall be bound (except to negotiate in good faith and as otherwise
provided herein) unless and until such license agreement is finally agreed upon and executed by both Parties.


 


		4.	INTELLECTUAL PROPERTY MATTERS



 


4.1       
Prior Intellectual Property. All patents, trade secrets, information, know-how, inventions, technology, data and other
intellectual property rights owned by either Party prior to the Effective Date shall remain the sole property of the respective
Party. For the avoidance of doubt, Krele shall retain all or its and its affiliates’ rights in patents, trade secrets, information,
know-how, inventions, technology, data and other intellectual property rights that relate to very low dose cyclobenzoprine (VLD-cyclo)
(the “Krele Intellectual Property”).


 


4.2       Developed
Intellectual Property. All patents, trade secrets, inventions, technology, and other intellectual property rights (collectively,
“Intellectual Property”) arising from the performance of the Feasibility Study shall be jointly
owned by Krele and Lipocine. Each of the Parties shall have the sole right to file patent applications related to their respective
Intellectual Property and the Parties shall mutually determine which Party shall file patent applications for jointly-owned Intellectual
Property. Each Party shall execute such assignments and other documents as the other Party may reasonably request to enable the
Parties to perfect assignments to the other Party of the Intellectual Property as provided herein and to protect the Intellectual
Property.


 


4.3       No
Implied or Express License. Unless and until Krele exercises the Option and the Parties enter into the license agreement contemplated
by such Option, Krele shall obtain no license or other rights under, and Lipocine grants no implied or express license to Krele
under, the Lipocine Intellectual Property for any use or purpose. In addition, Lipocine shall have no license or other rights under,
and Krele grants no implied or express license to Lipocine under, the Krele Intellectual Property for any use or purpose other
than performance of the Feasibility Study on behalf of Krele as contemplated by the Protocol and this Agreement.


 


4.4       Use
of Study Data and Name. Lipocine shall have the rights to use the data and results of the Feasibility Study (the “Study
Data”) for internal and marketing purposes (and not drug development), such as use of the Study Data in proposals,
presentations and similar materials supplied by Lipocine to its prospective partners or business partners for promotional or marketing
purposes only; provided, however, that Lipocine shall redact all references to Krele and Krele Intellectual Property and any confidential
or proprietary information from any Study Data supplied to the prospective customers or business partners of Lipocine and such
prospective customers and business partners will not be granted any rights or licenses (implied or express) in the Krele Intellectual
Property or Study Data. Upon execution of the license agreement, Krele shall have the right, but not any obligation, to use the
name “Lipocine” and “Lip’ral” on internal and marketing materials related to the Feasibility Study
and the results thereof, including any Products.


 



    	4



    	 



    

 


4.5       Ownership
of Study Data. Notwithstanding anything to the contract in Section 4.2, Krele shall own all work product, information and
data arising from the Feasibility Study regardless of whether the Option is exercised. 


 


		5.	TERM AND TERMINATION



 


5.1       Agreement
Term. Unless terminated earlier by either Party pursuant to this Section 3, this Agreement shall become effective upon the
Effective Date and shall terminate on the earlier of expiration of the Option. This Agreement may be extended by written agreement
signed by the Parties.


 


5.2       Termination
for Uncured Breach. If a Party breaches a material obligation, the other Party may give written notice to such breaching Party
specifying the breach and its intention to terminate this Agreement if such breach is not cured. If the breaching Party does not
cure the breach within sixty (60) days of receipt of such notice, the other Party may terminate the Agreement upon written notice
to the breaching Party.


 


5.3       Consequences
of Termination. Termination or expiration of this Agreement will not relieve either Party of any obligations under this Agreement
accrued prior to any such termination or expiration. The obligations of the Parties pursuant to Sections 4.1, 4.2, 4.3 and 6 shall
survive expiration or termination of this Agreement for the period set forth therein, and if no period is set forth, perpetually.


 


5.4       Early
Termination. Upon early termination of the Feasibility
Study, for reasons other than safety concerns of study subjects or other reasonable scientific or regulatory concerns, or for uncured
breach of the payment terms thereunder, the Option to license shall not survive.


 


		6.	CONFIDENTIALITY



 


6.1       Confidential
Treatment. All Information of a Party that is disclosed by such Party to the other Party pursuant to this Agreement and labeled
“confidential” or the equivalent (the “Confidential Information”) shall be maintained in
confidence by the recipient Party and its respective officers, employees, agents, assignees, and subcontractors for a period of
ten (10) years from the date of termination of the Agreement. During such period, recipient Party shall not publish or otherwise
disclose the Confidential Information of the disclosing Party to any other Party or entity and shall not use the Confidential Information
of the disclosing Party for purposes other than as expressly permitted in this Agreement, without the written consent of the other
Party.


 


6.2       Limited
Third Party Disclosure. Each Party may disclose the Confidential Information of the other Party to a third party only after
obtaining the prior written approval of the Party owning such Confidential Information for such disclosure and provided that each
such Third Party shall have agreed in writing to be bound by obligations of non-use and nondisclosure equivalent in all respects
to those assumed by the Parties hereunder.


 



    	5



    	 



    

 


6.3          Information
Excluded from Confidentiality Provision. The foregoing obligations of confidentiality and non-use shall not apply to materials
and information that the receiving Party can demonstrate:


 


(a)         are
or become publicly known or available through no fault or omission of the recipient;


 


(b)         are
learned or obtained by the recipient from a third party entitled to disclose or transfer such materials or information;


 


(c)         are
already known or possessed by the recipient before receipt or transfer from the disclosing Party, as shown by the recipient 's
prior written records; or


 


(d)         are
developed independently by an employee or consultant of the recipient with no knowledge of the Confidential Information
disclosed hereunder.


 


6.4       Other
Permitted Disclosure. Notwithstanding any other provision of this Agreement, a Party may disclose the Confidential Information
of the other Party to the limited extent that such disclosure:


 


		(a)	is in response to a valid
order of a court or other governmental body;
	 	 	 



		(b)	is required by law or regulation;



 


provided, however, that such Party shall
first have given reasonable prior notice to the other Party and shall have made a reasonable effort, or shall cooperate with the
other Party's efforts, as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the
Confidential Information so disclosed be used only for the purposes for which such order was issued or as required by such law
or regulation.


 


		7.	MISCELLANEOUS PROVISIONS



 


7.1       Execution
in Counterparts. This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered,
shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument.


 


7.2       Entire
Agreement. This Agreement constitutes, on and as of the Effective Date, the entire agreement between the Parties with respect
to the subject matter hereof, and all prior understanding and agreements, whether written or oral, between the Parties with respect
to such subject matter are hereby superseded in their entireties.


 


7.3       Governing
Law. This Agreement shall in all respects be governed by, and construed and enforced in accordance with, the laws of the State
of New York without regard to its conflict of laws principles.


 



    	6



    	 



    

 


7.4       Relationship
of the Parties. The Parties to this Agreement are independent contractors and not joint venturers or partners. Neither Party
shall be deemed to be an agent of the other Party as a result of any transaction under or related to this Agreement nor shall in
any way pledge the other Party’s credit or incur any obligation on behalf of the other Party.


 


7.5       Waiver.
The failure of either Party to insist upon strict compliance with any of the terms, covenants, or conditions herein shall not
be deemed a waiver by such Party of such terms, covenants or conditions, nor shall any waiver or relinquishment of any right at
any one or more times be deemed a waiver or relinquishment of such right at any other times, nor shall any single or partial exercise
of any right or remedy hereunder preclude any other or a future exercise thereof or the exercise of any other right or remedy granted
hereby or by any related document or by law.


 


7.6       Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.
Any provision declared invalid or unenforceable by a court of competent jurisdiction shall be deleted and the remaining terms and
conditions of this Agreement shall remain in full force and effect.


 


IN WITNESS WHEREOF,
the Parties hereto have caused this Agreement to be executed by their authorized representatives.


 


	LIPOCINE, INC.	 	KRELE PHARMACEUTICALS, INC.
	 	 	 
	By: 	/s/ GERALD T. SIMMONS	 	By:	/s/ SETH LEDERMAN
	Name: 	Gerald T. Simmons	 	Name: 	Seth Lederman
	 	 	 
	Title: 	Corporate Business Development Officer	 	Title: 	Chairman


 



    	7



    	 



    

 


Attachment A


 


Proposal for Feasibility Evaluation of


 


Improved Oral Delivery of Cyclobenzaprine


 





	 	March 30, 2007
	 	 
	 	Submitted By:
	 	 
	 	Lipocine, Inc.
	 	675 Arapeen Drive Suite 202
	 	Salt Lake City, Utah 84108
	 	 
	 	Submitted To:
	 	 
	 	Krele Pharmaceuticals, Inc.







 






    	8



    	 



    

 


Improved Oral Delivery of Cyclobenzaprine
- Feasibility Proposal


 


Background


 


Lipocine Inc. (Lipocine) has proprietary
technology, Lip’ralTM, for improved oral absorption of poorly water soluble drugs and elimination of food effects
on absorption. The technology has been validated in clinical and preclinical studies with several different poorly water soluble
drugs, and is protected by issued and pending patents.


  


Krele Pharmaceuticals (Krele) has contracted
Lipocine to conduct a feasibility evaluation for the improved oral delivery of Cyclobenzaprine, a muscle
relaxant. Cyclobenzaprine is currently sold under the brand name Flexeril® and
there are several generics. It is available as 5 mg, 7.5 mg and 10 mg tablets. 


 


The specific objectives of the feasibility
evaluation are:


 


		1.	Develop Lip’ralTM formulations of cyclobenzaprine at slightly lower strength than
the marketed product; select two formulations for a Phase I study.



 


		2.	Manufacture, test and release the lots under GMP. Conduct a Phase I clinical study to determine
whether the Lipocine formulations are bioequivalent to FlexerilÒ 5 mg
tablet.



 


The feasibility program involves pre-formulation,
formulation development and stability evaluation with the goal of selecting two formulations for a Phase I study. It also includes
manufacture, testing and release of clinical lots of the selected formulation and conducting a Phase I study to determine the pharmacokinetics
of the Lipocine formulations relative to FlexerilÒ.


 


The tasks, timelines
and cost of the feasibility program are presented in detail below.


 



    	9



    	 



    

 


Work Plan


 


	Salient
    Tasks	 	FTEs	 	Timeline
	Preformulation:

        §Develop
        analytical methods for assay/characterization of drug in different matrices (lipidic excipients, formulations etc.)

        §Determine
        drug solubility/compatibility in several lipidic components, and other excipients

        §Screen
        preliminary compositions for drug solubility/loading, and extent of drug solubilization upon dispersion in SGF
	 	0.17	 	6 weeks
	Formulation Development:

        §Optimize
        two (2) formulations to achieve target solubility enhancement, dosage form drug loading, release profile, etc.

        §Develop
        methods & confirm 1 month accelerated stability of formulations
	 	0.17	 	8 weeks
	TOTAL
    (Stage I)	 	0.34	 	16
    weeks


 


	Documentation,
        Process, Method Development:

        §Select
        two (2) formulations for clinical study

        §Specifications
        and STMs for raw materials, intermediates and finished products; develop cleaning method

        §Manufacture
        one trial lot to develop/confirm process, methods and specifications for finished product

        §Batch
        records for manufacture of clinical supplies

        §Protocol
        and CRO for Phase I study and bioanalysis
	 	0.25	 	3
    weeks
	Clinical
        Supplies, Stability:

        §Procure,
        test and release raw materials

        §Manufacture,
        test and release two clinical lots under GMP compliance

        §Stage
        and conduct ICH stability program on the clinical lots
	 	0.25	 	3 weeks
	Conduct Phase I Studies:

        §Select
        CROs

        §Coordinate
        insurance, IRB review, shipping supplies, etc.

        §Monitor
        study

        §Complete
        PK and statistical analysis

        §Draft
        and Final clinical study reports
	 	0.10

        All
        external costs will be passed through 
	 	16
    weeks
	TOTAL
    (Stage II)	 	0.60	 	22
    weeks


 



    	10



    	 



    




 


Cost & Payment Terms 


 


Based on Lipocine’s 2007 fully burdened
reimbursement rate of $280,000/FTE, the cost of Stage I of the feasibility program is $95,200. The payment terms for Stage I are
as follows:


  


50% upon signing of the agreement;


 


50% upon selection
of two formulations for a Phase I study.


 


The cost for Stage II of the feasibility
program is $168,000 (plus external costs) paid according to the following schedule:


 


50% upon Krele’s decision
to proceed with Stage II


 


25% upon IRB approval of the
Phase I study protocol


 


20% upon submission of the preliminary
pharmacokinetic data


 


5% upon completion of the final
clinical study report


 


All external costs (clinical study, liability
insurance premium, bioanalytical costs, travel for clinical study monitoring) and significant (>$500) material costs (HPLC columns,
raw materials etc.) will be passed through to Krele.


 


Lipocine will invoice Krele for the amount
due upon completion of the associated milestone. All invoices are payable net 30 days.


 


Lipocine Responsibilities


 


Lipocine will purchase cyclobenzaprine
API in order to complete the feasibility program.


 


Lipocine will develop/verify
analytical method(s) for assay of cyclobenzaprine in components and formulations.


 


Lipocine will conduct preformulation
and formulation development studies as per Stage A Work Plan.


 


At the conclusion of formulation
development phase, Lipocine and Krele will select two (2) formulations for clinical development.


 


Upon a go decision from Krele,
Lipocine will manufacture, test and release lots of the two (2) selected formulations for the Phase I study as per Work Plan.


 


Lipocine will develop the study
protocols and select CROs in consultation with Krele as per Work Plan.


 


Lipocine will conduct the Phase
I program as per Work Plan.


 


Lipocine will provide periodic
written project reports to Krele.


 








    	11